Research profile 11Istraživački profil 11
An α-MSH-derived tripeptide with anti-inflammatory signals in cell, tissue and animal models. Human efficacy, pharmacokinetics and safety have not been established.Tripeptid izveden iz α-MSH sa antiinflamatornim signalima u ćelijskim, tkivnim i životinjskim modelima. Efikasnost, farmakokinetika i bezbednost kod ljudi nisu utvrđene.
A research category organizes reading. It is not a promise of an individual outcome.Istraživačka kategorija organizuje čitanje. Ona nije obećanje individualnog ishoda.
Plain-language overviewJasan pregled
KPV is the carboxyl-terminal tripeptide of α-melanocyte-stimulating hormone: lysine–proline–valine. Experiments suggest that this short sequence can influence inflammatory signalling without simply reproducing the classic melanocortin-receptor pathway of the parent hormone.KPV je karboksil-terminalni tripeptid α-melanocite stimulišućeg hormona: lizin–prolin–valin. Eksperimenti ukazuju da ova kratka sekvenca može uticati na inflamatornu signalizaciju bez jednostavnog ponavljanja klasičnog puta melanokortinskih receptora matičnog hormona.
The most developed research line concerns intestinal inflammation. KPV entered intestinal epithelial and immune-cell models through the PepT1 transporter, reduced NF-κB and MAP-kinase signalling, and reduced inflammatory readouts in chemically induced mouse colitis. Later nanoparticle and hydrogel systems improved delivery in mouse or rat models. Those formulation-dependent animal results do not show that an ordinary oral, topical or injectable KPV product treats inflammatory bowel disease in people.Najrazvijenija istraživačka linija odnosi se na upalu creva. KPV je ulazio u modele intestinalnih epitelnih i imunskih ćelija preko transportera PepT1, smanjivao signalizaciju NF-κB i MAP-kinaze i inflamatorne pokazatelje u hemijski izazvanom kolitisu kod miševa. Kasniji sistemi nanočestica i hidrogelova poboljšali su isporuku u modelima na miševima ili pacovima. Ti rezultati na životinjama, zavisni od formulacije, ne pokazuju da običan oralni, topikalni ili injekcioni KPV leči inflamatornu bolest creva kod ljudi.
Skin and antimicrobial claims are also preclinical. KPV has been studied in keratinocytes, a three-dimensional skin model and laboratory assays involving Staphylococcus aureus and Candida albicans. These models can justify further research, but they are not clinical evidence for eczema, psoriasis, wound healing, infection treatment or cosmetic benefit.Tvrdnje o koži i antimikrobnom dejstvu takođe su pretkliničke. KPV je proučavan u keratinocitima, trodimenzionalnom modelu kože i laboratorijskim testovima sa Staphylococcus aureus i Candida albicans. Ovi modeli mogu opravdati dalja istraživanja, ali nisu klinički dokaz za ekcem, psorijazu, zarastanje rana, lečenje infekcija ili kozmetičku korist.
In its July 2026 compounding review, FDA stated that it had not identified clinical studies or human-exposure data for KPV by any route and proposed that KPV free base and KPV acetate not be included on the section 503A Bulks List. That proposal is a regulatory assessment of the available record—not proof that every biological hypothesis is false—but it sharply limits responsible human-health claims.U proceni izrade lekova iz jula 2026, FDA je navela da nije pronašla kliničke studije niti podatke o izloženosti ljudi KPV-u bilo kojim putem i predložila da se KPV slobodna baza i KPV acetat ne uključe na 503A listu aktivnih supstanci. Taj predlog je regulatorna procena dostupnih podataka—a ne dokaz da je svaka biološka hipoteza pogrešna—ali snažno ograničava odgovorne tvrdnje o zdravlju ljudi.
Read the educational boundaryPročitajte edukativnu granicuSelected sources & official recordsOdabrani izvori i zvanični zapisi
These are curated starting points, not an exhaustive bibliography. Live PubMed and ClinicalTrials.gov searches below expose the broader and changing record.Ovo su odabrane polazne tačke, a ne iscrpna bibliografija. Pretrage uživo na PubMed-u i ClinicalTrials.gov u nastavku prikazuju širi zapis koji se menja.
Laboratory assays reported activity of α-MSH and KPV against S. aureus and C. albicans. The experiment did not test treatment of human infection.Laboratorijski testovi prijavili su aktivnost α-MSH i KPV protiv S. aureus i C. albicans. Eksperiment nije ispitivao lečenje infekcije kod ljudi.
KPV reduced leukocyte accumulation in mouse peritonitis models through a pattern that differed from classic melanocortin-receptor signalling.KPV je smanjio nakupljanje leukocita u modelima peritonitisa kod miševa obrascem koji se razlikovao od klasične signalizacije melanokortinskih receptora.
The study linked KPV uptake to PepT1 in cell systems and reported reduced inflammatory readouts in two chemically induced mouse-colitis models.Studija je povezala unos KPV-a sa PepT1 u ćelijskim sistemima i prijavila smanjene inflamatorne pokazatelje u dva hemijski izazvana modela kolitisa kod miševa.
A nanoparticle-plus-hydrogel system improved colon delivery and reduced inflammatory and histological measures in mice. The delivery platform was part of the intervention.Sistem nanočestica i hidrogela poboljšao je isporuku u kolon i smanjio inflamatorne i histološke pokazatelje kod miševa. Platforma za isporuku bila je deo intervencije.
A targeted nanoparticle/hydrogel formulation improved mucosal-healing and inflammatory measures in a mouse ulcerative-colitis model.Ciljana formulacija nanočestica i hidrogela poboljšala je pokazatelje zarastanja sluznice i upale u modelu ulceroznog kolitisa kod miševa.
KPV reduced selected oxidative-stress, inflammatory and cell-death signals in HaCaT keratinocytes and a 3D skin model. This was not a patient trial.KPV je smanjio odabrane signale oksidativnog stresa, upale i ćelijske smrti u HaCaT keratinocitima i 3D modelu kože. Ovo nije bila studija na pacijentima.
FDA reported no identified human clinical or exposure data and proposed that KPV free base and KPV acetate not be included on the 503A Bulks List.FDA je navela da nije pronašla kliničke podatke niti podatke o izloženosti ljudi i predložila da se KPV slobodna baza i KPV acetat ne uključe na 503A listu.
Search results can change as papers and trial records are added or updated.Rezultati pretrage mogu se menjati kako se radovi i zapisi studija dodaju ili ažuriraju.
Evidence by questionDokazi prema pitanju
Evidence strength depends on the exact claim. A mechanistic signal, a biomarker shift and a patient-centred outcome are not interchangeable endpoints.Snaga dokaza zavisi od tačne tvrdnje. Mehanistički signal, promena biomarkera i ishod važan za pacijenta nisu zamenljive krajnje tačke.
PepT1-mediated uptake and lower inflammatory signalling were reported; targeted delivery systems improved preclinical effects.Prijavljeni su unos preko PepT1 i slabija inflamatorna signalizacija; ciljani sistemi isporuke poboljšali su pretkliničke efekte.
No demonstrated treatment effect in people with IBD.Nije dokazan terapijski efekat kod ljudi sa IBD.KPV reduced selected oxidative-stress and inflammatory readouts after particulate-matter exposure.KPV je smanjio odabrane pokazatelje oksidativnog stresa i upale nakon izlaganja česticama.
No patient trial for dermatitis, psoriasis, wounds or cosmetic outcomes.Nema studije na pacijentima za dermatitis, psorijazu, rane ili kozmetičke ishode.Early laboratory work reported activity against S. aureus and C. albicans.Rani laboratorijski rad prijavio je aktivnost protiv S. aureus i C. albicans.
Laboratory activity is not evidence that KPV treats an infection.Laboratorijska aktivnost nije dokaz da KPV leči infekciju.FDA reported finding no clinical studies or human-exposure data by any route in its 2026 review.FDA je u proceni iz 2026. navela da nije pronašla kliničke studije niti podatke o izloženosti ljudi bilo kojim putem.
Safety, pharmacokinetics, effective exposure and long-term outcomes remain unknown.Bezbednost, farmakokinetika, efektivna izloženost i dugoročni ishodi ostaju nepoznati.2026 regulatory checkpointRegulatorna tačka provere 2026
FDA's July 2026 review covered KPV free base and KPV acetate for wound healing and inflammatory conditions. The agency said effectiveness could not be evaluated, human safety risks were unknown and the substances were not sufficiently characterized for the proposed 503A listing.FDA procena iz jula 2026. obuhvatila je KPV slobodnu bazu i KPV acetat za zarastanje rana i inflamatorna stanja. Agencija je navela da se efikasnost ne može proceniti, da su rizici po bezbednost ljudi nepoznati i da supstance nisu dovoljno okarakterisane za predloženo uvrštavanje na 503A listu.
No adverse-event reports is not the same as evidence of safety when exposure is poorly documented and reporting is incomplete.Odsustvo prijava neželjenih događaja nije isto što i dokaz bezbednosti kada je izloženost slabo dokumentovana, a prijavljivanje nepotpuno.
Analytical realityAnalitička realnost
A certificate can answer only the questions its methods actually tested. Route, formulation and raw-material provenance determine which additional quality controls matter.Sertifikat može odgovoriti samo na pitanja koja su njegove metode zaista ispitale. Put primene, formulacija i poreklo sirovine određuju koje su dodatne kontrole kvaliteta važne.
Name the exact bulk substance: KPV free base and KPV acetate are not interchangeable labels.Navesti tačnu aktivnu supstancu: KPV slobodna baza i KPV acetat nisu zamenljive oznake.
Use sequence-appropriate identity testing, such as LC–MS, rather than relying on appearance or a supplier label.Koristiti ispitivanje identiteta prilagođeno sekvenci, kao što je LC–MS, umesto oslanjanja na izgled ili etiketu dobavljača.
Report quantitative content separately from chromatographic purity and related-peptide impurities.Kvantitativni sadržaj prijaviti odvojeno od hromatografske čistoće i srodnih peptidnih nečistoća.
Characterize counterion, water, residual solvents and other synthesis-related impurities where relevant.Kada je relevantno, okarakterisati kontra-jone, vodu, rezidualne rastvarače i druge nečistoće povezane sa sintezom.
For any material claimed to be injectable, endotoxin and sterility are separate release questions; chemical purity cannot answer them.Za svaki materijal za koji se tvrdi da je injekcioni, endotoksini i sterilnost su odvojena pitanja oslobađanja serije; hemijska čistoća ne može odgovoriti na njih.
Stability must be demonstrated for the actual formulation, container, temperature and time—not borrowed from another peptide or delivery system.Stabilnost se mora dokazati za stvarnu formulaciju, ambalažu, temperaturu i vreme—a ne preuzeti od drugog peptida ili sistema isporuke.
Future verificationBuduća verifikacija
A KPV record must identify the exact molecular form, confirm the Lys–Pro–Val sequence, report assay and chromatographic purity separately, characterize relevant synthesis impurities and display microbiological results only when those tests were actually performed. Preclinical literature cannot authenticate a vial or establish suitability for human use.KPV zapis mora navesti tačan molekulski oblik, potvrditi sekvencu Lys–Pro–Val, odvojeno prijaviti sadržaj i hromatografsku čistoću, okarakterisati relevantne nečistoće sinteze i prikazati mikrobiološke rezultate samo kada su ti testovi zaista sprovedeni. Pretklinička literatura ne može potvrditi autentičnost bočice niti pogodnost za primenu kod ljudi.
Understand the test fieldsRazumite polja testiranja